默克
MRK
145.95
+0.76
+0.52%
默克
US · MRK
#43 按市值排名
上市于 1970
145.95
+0.76
+0.52%
实时 - 追踪5344个代码 - 心跳于443秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了10家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 81.53% +0.00pp
- 机构数量
- 4,346 -10
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund68.39%
Public Company4.80%
Private Company2.38%
Government Pension Fund2.09%
Sovereign Wealth Fund1.59%
Hedge Fund1.06%
Family Office/Trust0.45%
Insurance Company0.28%
Corporate Pension Plan0.19%
Other18.77%
主要股东 截至 2026-06-30
BlackRock
9.20% · 227.00M 股
Vanguard Capital Management, LLC
7.10% · 175.19M 股
State Street Global Advisors
4.88% · 120.41M 股
Wellington Management Group
3.50% · 86.25M 股
Vanguard Portfolio Management, LLC
2.75% · 67.74M 股
Other
72.58%
Geode Capital Management, LLC
2.46% · 60.74M 股
Charles Schwab Investment Management
2.20% · 54.37M 股
Fisher Investments
1.56% · 38.52M 股
Norges Bank Investment Management
1.50% · 36.98M 股
UBS Asset Management
1.35% · 33.29M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 41次买入 · 8次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Robert Davis | Chairperson & CEO | 0.02% |
| Sanat Chattopadhyay | Executive VP & President of Merck Manufacturing Division | 0.01% |
| Richard DeLuca | Executive VP & President of Merck Animal Health | 0.00% |
| Dean Li | Executive VP & President of Merck Research Laboratories | 0.00% |
| Caroline Litchfield | Chief Financial Officer | 0.00% |
| Jennifer Zachary | Executive Vice President | 0.00% |
| Chirfi Guindo | Senior VP & Chief Marketing Officer for Merck Human Health | 0.00% |
| David Williams | Executive VP and Chief Information & Digital Officer | 0.00% |
| Joseph Romanelli | Senior VP & President of Human Health International | 0.00% |
| David Maraldo | Executive VP & President of Merck Manufacturing Division | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-29 | Christine Seidman | Independent Director | Other Derivative Acquisition | +55 | -- |
| 2026-09-29 | Surendralal Karsanbhai | Director | Other Derivative Acquisition | +111 | -- |
| 2026-09-29 | Mary Coe | Independent Director | Other Derivative Acquisition | +206 | -- |
| 2026-08-31 | Gaurav Gupta | Executive Vice President and Chief Information & Digital Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-08-12 | Chirfi Guindo | Senior VP & Chief Marketing Officer for Merck Human Health | Open Market Disposition | -10,000 | $135.00 |
| 2026-08-11 | Richard DeLuca | Executive VP & President of Merck Animal Health | Open Market Disposition | -45,320 | $130.43–132.35 |
| 2026-08-11 | Jennifer Zachary | Executive Vice President | Open Market Disposition | -25,388 | $133.46 |
| 2026-08-11 | Jennifer Zachary | Executive Vice President | Derivative Exercise and Sale | -54,927 | $84.71–133.46 |
| 2026-08-05 | Richard DeLuca | Executive VP & President of Merck Animal Health | Open Market Disposition | -6,050 | $130.23–131.02 |
| 2026-08-05 | Chirfi Guindo | Senior VP & Chief Marketing Officer for Merck Human Health | Open Market Disposition | -15,000 | $131.00 |
| 2026-08-04 | David Williams | Executive VP and Chief Information & Digital Officer | Derivative Exercise and Sale | -52,847 | $73.73–128.77 |
| 2026-08-04 | David Maraldo | Executive VP & President of Merck Manufacturing Division | Derivative Exercise and Sale | -18,706 | $73.73–128.72 |
| 2026-06-29 | Christine Seidman | Independent Director | Other Derivative Acquisition | +63 | -- |
| 2026-06-29 | Surendralal Karsanbhai | Director | Other Derivative Acquisition | +126 | -- |
| 2026-06-29 | Mary Coe | Independent Director | Other Derivative Acquisition | +233 | -- |
| 2026-05-28 | Pamela Craig | Independent Director | Other Derivative Acquisition | +1,853 | -- |
| 2026-05-28 | Patricia Russo | Independent Director | Other Derivative Acquisition | +1,853 | -- |
| 2026-05-28 | Thomas Glocer | Lead Independent Director | Other Derivative Acquisition | +1,853 | -- |
| 2026-05-28 | Risa Lavizzo-Mourey | Independent Director | Other Derivative Acquisition | +1,853 | -- |
| 2026-05-28 | Douglas Baker | Independent Director | Other Derivative Acquisition | +1,853 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:10 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
the keytruda patent cliff is a few years out but the market’s already discounting it hard. pipeline needs to deliver or this stays cheap for a while, that’s the whole debate in one sentence.